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 78 
 79 
The prevalence and cost of diabetes is growing rapidly worldwide (1). People with 80 
diabetes are twice as likely to be admitted to hospital, and at least 10% of those in hospital 81 
have diabetes at any one time (2). In some age groups, it is as many as one in five (3). The 82 
associated costs of excess admissions, as well as increased costs per admission, are 83 
significant contributors to the financial burden borne by healthcare systems from 84 
diabetes and often reflect preventable morbidity suffered by patients (4).  85 
  86 
Previously, two prediction tools have been developed, both based on secondary care 87 
data, to identify those with diabetes, at high risk of either all-cause excessive length of 88 
stay or all-cause inpatient mortality over four years (5), or all-cause re-admission within 30 89 
days among hospitalised patients (6). However, the practical application of both 90 
prediction models was limited by lack of external validation, non-specificity for people 91 
with type 2 diabetes, the use of predictors derived from secondary care rather than 92 
primary care data, variations on predictors recorded in different datasets (e.g. 93 
comorbidity) and a relative short time-gap between bȋ ? ?ǯ94 
readmission). 95 
Among hospital admissions, cardiovascular events are the major cause for hospitalisation 96 
in people with type 2 diabetes (7). Although risk factors such as blood pressure and 97 
HbA1c are recognised as warranting intervention on their own (8), (9), there has been no 98 
current algorithm to estimate the absolute risk of cardiovascular hospitalisation and 99 
rehospitalisation in people with type 2 diabetes.  100 
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Using a model to make predictions for individual patients with type 2 diabetes is more 101 
comprehensive than using individual risk factors, and is preferred to the risk grouping 102 
approach (10), (11).  103 
The aim of our study was to develop and externally validate new prediction models based 104 
on reliable clinical measurements in primary care settings for cardiovascular 105 
hospitalisation over the next 2 years and cardiovascular re-hospitalisation up to 90 days 106 
following a prior cardiovascular hospitalisation. 107 
 108 
MATERIALS AND METHODS 109 
 110 
 We utilised two cohorts from Cambridgeshire, England: one (Derivation) based on the 111 
electronic health record data from primary care settings to develop our cardiovascular 112 
hospitalisation and re-hospitalisation risk scores and another (Validation) based on post-113 
trial cohort data for external validation.  114 
 115 
 116 
Patient lists from 18 general practices across Cambridgeshire, England, in 2008/2009 were 117 
collated and linked with hospital admissions (Secondary Uses Service (SUS)) data as part 118 
of an evaluation of diabetes care across the county by the local health board, National 119 
Health Service (NHS) Cambridgeshire. This cohort was limited to volunteer practices 120 
using the Egton Medical Information Systems (EMIS) general practitioner (GP) software 121 
system, from which a predefined set of data could be extracted. There was no systematic 122 
selection process for these surgeries, and data extracted were for their entire diabetes 123 
population. All patients with diabetes had follow-up hospitalisation data to 2010Ȃ2011. 124 
Hospital admissions to NHS and private hospitals within and outside Cambridgeshire 125 
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were followed-up. No personal identifiers were released to researchers, and all 126 
subsequent analyses were conducted on anonymised datasets.  127 
 128 
The design and methods of the RAPSID trial have been published previously (12), as have 129 
its CONSORT (Consolidated Standards of Reporting Trials) diagram and the results of its 130 
primary outcomes (12).  Briefly, RAPSID was a 2x2 factorial cluster RCT comparing 4 131 
groups: Controls, 1:1 (individual) peer support, group peer support, and combined 1:1 and 132 
group peer support among patients with type 2 diabetes. Participants had their diabetes 133 
for at least 12 months and those with dementia or psychotic illness were excluded. 134 
Participants were recruited from communities across Cambridgeshire and neighbouring 135 
areas of Essex and Hertfordshire.  Follow up data were only available for participants in 136 
Cambridgeshire and neighbouring areas of Hertfordshire that are served by the 137 
Cambridgeshire and Peterborough Clinical Commissioning Group (CCG). Clusters were 138 
ȋǮǯȌǤ139 
developed following a pilot (13), using a framework defined by Peers for Progress (14).  140 
Peers facilitating peer support were termed peer support facilitators and there selection, 141 
training, support and the overall programme are described elsewhere (15).      The 142 
intervention lasted 8-12 months and was commenced and concluded, cluster by cluster, 143 
between 02/06/11 to 12/04/12.  Ethics approval was received from the Cambridgeshire 144 
REC2 Committee (10/H0308/72), and signed consent included agreement for access to 145 
hospital data.   146 
At baseline, demographic data, blood pressure, and HbA1c and lipid profiles information 147 
were collected. Each participant was followed up until June 2015 (0.91- ?Ǥ ? ?ǯ -148 
up from beginning/entry into the trial).  Hospitalisation (NHS hospitals & private 149 
hospitals), Accident & Emergency (A&E) and outpatient visits within/outside 150 
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Cambridgeshire and the included areas of Hertfordshire were completely collected 151 
through Cambridgeshire and Peterborough Clinical CCG (16) and the elective/non-elective 152 
status, and International Classification of Diseases (ICD-10) codes (8).  153 
Ǧ 154 
The primary outcome of the study was having at least one hospitalisation with 155 
cardiovascular disease (CVD) as the primary diagnosis (ICD-10: I20ȂI25, I60ȂI69 and I73 in 156 
the first ICD field) over the 2-year follow-up and having at least one CVD re-hospitalisation 157 
after 90 days of prior CVD hospitalisation.  158 
ǡǡ 159 
To achieve the maximum extrapolation application of our risk algorithm, objective clinical 160 
measurements were used as predictors in the model, including body mass index (BMI) , 161 
blood pressure (systolic (SBP) and diastolic (DBP))  and the metabolic variables glycated 162 
haemoglobin (HbA1c) and lipid profiles.  We also included demographic characteristics, 163 
(age and gender) and whether the patient was on lipid lowering treatment. Patients with 164 
diabetes were invited to have their blood pressure and metabolic variables measured at 165 
least once a year after the diagnosis of diabetes and the most recent was taken before 1 166 
April 2009 (a minimum of 50 days before the first admission). Diabetes duration was not 167 
universally recorded, and hence was not usefully available for analysis. Diabetes therapy 168 
was not included in the dataset. Lipid-lowering treatment was recorded. 169 
Our derivation cohort had missing information on body mass index (3.17%), systolic blood 170 
pressure (9.95%), diastolic blood pressure (9.95%), total cholesterol (12.35%), high density 171 
lipoprotein (14.56%), and low density lipoprotein (16.27%). We used multiple imputation to 172 
replace missing values by using a chained equation approach based on all candidate 173 
predictors and outcomes. We created 16 imputed datasets for missing variables that were 174 
ǯǤ175 
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Limited information was missing (<1%) in our external validation dataset and the complete 176 
dataset was used in our analysis. On the basis of an estimated 588 cardiovascular 177 
hospitalisations and 316 cardiovascular re-hospitalisations and 16 predictors or levels in 178 
our derivation cohort, we had an effective sample size of 37 cardiovascular 179 
hospitalisation and 21 cardiovascular re-hospitalisation per predictor or level, above the 180 
minimum requirement suggested by Peduzzi et al (17). 181 
 182 
The derivation cohort work had approval from the Cambridgeshire research ethics 183 
committee as part of a wider service evaluation. Ethics approval for validation cohort was 184 
received from the Cambridgeshire REC2 Committee (10/H0308/72), and signed consent 185 
included agreement for access to hospital data.   186 
 187 
We treated incidence occurrence of cardiovascular hospitalization after the first 90 days 188 
since the start of follow-up and the incident occurrence of cardiovascular re-189 
hospitalisation as binary outcome measures. For each of the 15 candidate predictors or 190 
levels, we used a univariate logistic regression model to calculate the unadjusted odds 191 
ratios. For derivation of the risk prediction model, we initially included all candidate 192 
predictors in a multivariable logistic regression model. We used fractional polynomials to 193 
model potential non-linear relationships between continuous predictors and outcome. 194 
Through backward elimination, we excluded lower lipid treatment from the multivariate 195 
model as it was not statistically significant (P>0.1 based on change in log likelihood). After 196 
elimination, we reinserted the excluded predictor into the final model to further check 197 
whether it became statistically significant. We also rechecked fractional polynomial terms 198 
at this stage and re-estimated them if necessary. We formed the risk equations for 199 
predicting the log odds of cardiovascular hospitalisation and cardiovascular re-200 
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hospitalisation by using the estimated regression coefficients multiplied by the 201 
corresponding predictors included in our models together with the intercepts. This 202 
process ultimately led to equations for the predicted risk=1/(1+e-riskscoreȌǡǲ203 
ǳ cardiovascular hospitalisation or cardiovascular re-204 
hospitalisation from the developed models. 205 
To facilitate model utilisation in clinical practice, the logistic regression equations were 206 
transformed into prognostic score charts. The coefficients in the logistic regression 207 
equation were multiplied by 50 and rounded to the nearest integer to obtain the 208 
prognostic score per predictor. Multiplication by 50 was chosen to get the majority of the 209 
coefficients close to an integer, thereby minimizing the effects of rounding. The sum of 210 
ǯ211 
cardiovascular re-hospitalisation. 212 
We assessed the performance of the models in terms of the C statistics and calibration 213 
slope (where 1.00 is ideal). The C statistics represents the probability that for any 214 
randomly selected pair of people with type 2 diabetes with and without outcomes, the 215 
patient with outcomes had a higher predicted risk (18). A value of o.50 indicated no 216 
discrimination and 1.00 represents perfect discrimination. We then undertook internal 217 
validation to correct measures of predictive performance for optimism (over-fitting) by 218 
bootstrapping 100 samples of the derivation data. We repeated the model derivation 219 
process in each bootstrap sample to produce a model, applied the model to the same 220 
bootstrap sample to quantify apparent performance, and applied the model to the 221 
original dataset to test model performance (calibration slope and C-statistics) and 222 
optimism (difference in the test performance and apparent performance). We then 223 
estimated the overall optimism across all models.   224 
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We applied our risk prediction model to each patient with type 2 diabetes in the external 225 
validation cohort on the basis of the presence of one or more predictors. We examined 226 
the performance of this final model both in the derivation dataset and then in external 227 
validation dataset in terms of discrimination by calculating the C statistics. We examined 228 
calibration by plotting agreement between predicted and observed risks across tenth of 229 
the predicted risks.  230 
We used Stata V14.0 for all statistical analyses. This study was conducted and reported in 231 
line with the Transparent Reporting of a multivariate prediction model for Individual 232 
Prediction Diagnosis (TRIPOD) guidelines (19). 233 
 234 
The sponsors of the study had no role in study design, data collection, data analysis, data 235 
interpretation, or writing of the report.  236 
 237 
 238 
In our derivation cohort, we analysed information on 4,704 type 2 diabetes patients with 239 
588 cardiovascular hospitalisations within 2 years and 316 re-hospitalisations after 90 240 
days since a prior cardiovascular hospitalisation. Our validated cohort had information on 241 
1,121 type 2 diabetes patients with 183 cardiovascular hospitalisations and 78 re-242 
hospitalisations. Table-1 summarises the basic characteristics and potential predictors of 243 
the study population. Patients with type 2 diabetes in both cohorts had similar age, 244 
gender, blood pressure and total cholesterol. Patients in the derived cohort had a higher 245 
level of high density lipoprotein, low density lipoprotein, and HbA1c. Compared with the 246 
derivation cohort, those in the validation cohort were more likely to be prescribed 247 
lowering lipid medicine and had more cardiovascular hospitalisation and re-248 
hospitalisation.  249 
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ǡǡ 250 
In the derivation dataset, the absolute risks of cardiovascular hospitalisation within 2 251 
years and re-hospitalisation within 9o days post cardiovascular hospitalisation were 12.5% 252 
and 6.7%, respectively. Univariable associations between cardiovascular hospitalisation 253 
and cardiovascular re-hospitalisation are listed in supplemental Table-1. Of the 10 254 
candidate predictors (16 categories), 9 predictors (15 categories) were statistically 255 
significantly associated with cardiovascular hospitalisation and re-hospitalisation in the 256 
final multivariable model (Table-2). Table-2 shows apparent and internal validation 257 
performance statistics of the risk prediction model. After adjustment for optimism, the 258 
final risk prediction model was able to discriminate type 2 diabetes patients with and 259 
without cardiovascular hospitalisation with a C statistics of 0.7094 (95% confidence 260 
interval 0.7067 to 0.7205), and discriminate type 2 diabetes patients with and without 261 
cardiovascular re-hospitalisation with a C statistics 0.7118 (0.7077 to 0.7159). The 262 
agreement between the observed and predicted proportion of cardiovascular 263 
hospitalisation and re-hospitalisation showed good apparent calibration (Figure-1, top left 264 
for cardiovascular hospitalisation and top right for cardiovascular re-hospitalisation). The 265 
optimism adjusted calibration slope was 1.0301 (0.9856 to 1.0747) and 1.0001 (0.9711 to 266 
1.0247) for cardiovascular hospitalisation and re-hospitalisation, respectively (Table-3).  267 
 268 
In the external validation cohort, the absolute risks for cardiovascular hospitalisation and 269 
re-hospitalisation were 16.3% and 7.0%, respectively. Applying our final risk prediction 270 
model to the independent population gave a C statistic of 0.7092 (0.7033 to 0.7151) for 271 
cardiovascular hospitalisation and 0.7098 (0.7014 to 0.7182) for cardiovascular re-272 
hospitalisation, and good calibration (Figure-1, bottom left for cardiovascular 273 
hospitalisation and bottom right for cardiovascular re-hospitalisation), with the 274 
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calibration slope 1.0001 (0.9807 to 1.0195) and 0.9981 (0.9948 to 1.0482) for 275 
cardiovascular hospitalisation and re-hospitalisation, respectively. 276 
Performance at the threshold for 10% and 20% of patients at highest risk 277 
Table-4 shows the sensitivity, specificity, and observed risk for the 5%, 10%, 15%, 20% and 278 
25% of patients at the highest predicted risk of each outcome in the validation cohort 279 
shown for illustrative purposes. For example, when a risk threshold of 24.53% for 280 
cardiovascular hospitalisation and 7.93% for cardiovascular re-hospitalisation is used to 281 
identify the 20% at highest predicted risk, the sensitivity was 33.40% for cardiovascular 282 
hospitalisation and 45.20% for cardiovascular re-hospitalisation, the specificity was 84.60% 283 
for cardiovascular hospitalisation and 75.90% for cardiovascular rehospitalisation, and the 284 
observed risk was 30.09% for cardiovascular hospitalisation and 11.98% for cardiovascular 285 
re-hospitalisation, respectively. 286 
 287 
Clinical examples 288 
Supplemental Chart-1 gives a clinical example of the application of prognostic score 289 
charts with graphical illustrations for cardiovascular hospitalisation and re-hospitalisation 290 
risk prediction models to predict 2-year risk of cardiovascular hospitalisation and risk of 291 
re-hospitalisation within 90 days of a prior cardiovascular hospitalisation.   292 
 293 
 294 
We have developed two new risk prediction models to estimate the absolute risk of 295 
cardiovascular hospitalisation within 2 years and cardiovascular re-hospitalisation after 90 296 
days of prior cardiovascular hospitalisation in a cohort of patients with type 2 diabetes in 297 
England. We then externally validated this model in another English cohort. The two 298 
prediction models had excellent calibration and useful discrimination, with C statistics of 299 
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greater than 0.70 both in the derivation cohort and external validation cohort. The two 300 
prediction models were built from clinical variables usually recorded and accessible in 301 
primary care settings, implying that they can be readily applied in routine primary care. 302 
Strengths and limitations 303 
Our two risk algorithms have several advantages over those in utilisation in many 304 
developed countries. Our models are based on absolute risks determined and validated in 305 
two independent populations. The models are developed from routinely recorded 306 
demographic and clinical measurements in primary care settings, which suggests that 307 
they can be straightforwardly applied in general practice and are readily amenable for 308 
further external validations in countries that have routine recorded data accessible for 309 
such aims. And the two risk algorithms can be easily integrated into online calculators for 310 
implementation in general practices. 311 
The methods used to derive and validate the model are similar to those for other risk 312 
prediction algorithms derived from the CPRD and QResearch databases (20), (21). The 313 
majority of predictors in our final model are accurate and reliable clinical measurements 314 
(22) routinely recorded in primary care settings and updated and reviewed for patients 315 
with type 2 diabetes, and are less varied than in other datasets. Moreover, the proportion 316 
of missing values was low, which would lead to little variation in external applications, 317 
although multiple imputation was still applied in our study. We acknowledge that our 318 
prediction models do not take into account diabetes duration, antidiabetes treatments, 319 
anti-hypertensive treatments, prior history of cardiovascular diseases, other diabetes 320 
complications (e.g. renal failure), lifestyle risk factors (like smoking), and other 321 
comorbidities due to limitations in the original data due to limitations in the original data, 322 
but we feel that the clinical measurements included in our models could be proxies for 323 
missing predictors.  Data limitations also prevented extending our model to all diabetes 324 
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complications rather than those relating to cardiovascular hospitalisation.  The relatively 325 
low sensitivities of our models to identify individuals at high risk of cardiovascular 326 
hospitalisation and re-hospitalisation is another limitation of the study. Due to the 327 
similarity between the derivation and validation cohorts, further external validation (e.g. 328 
cohorts from other countries) are warranted. 329 
Comparison with other studies 330 
Nirantharakumar et al. developed a prediction model among patients with diabetes to 331 
estimate adverse events (either excessive length of stay or inpatient mortality) over 4 332 
years using a secondary care dataset in Birmingham, England (5). The predictors applied 333 
in this model covered demographic characteristics, clinical pathological test results, and 334 
use of insulin, recorded within 72 hours of hospitalisation. That population represented 335 
the people with at least previous inpatient hospitalisation, and probably reflects a cohort 336 
with more severe conditions, and likely higher prior probabilities of an event. The ranges 337 
of clinical measurements during a hospital admission would tend to be greater than in the 338 
community, as patients would be sicker and e.g. blood glucose control could be the 339 
reason for hospitalisation, or exacerbated by acute illness, making the dataset difficult to 340 
use as a basis for a prediction tool in routine care. Most importantly, this prediction 341 
model has not been externally validated and the model performance needs to be further 342 
evaluated in external populations before its application in clinical practices.  343 
Rubin et al developed a tool to predict the risk of all-cause re-admission within 30 days 344 
among hospitalised patients with diabetes using hospitalised data (6). The short time-gap 345 
between predictor measurements and outcome made the tool less useful for clinical 346 
practice. The reasons for hospitalisation could be quite mixed, with different pathway 347 
and potential interventions. Therefore, using the all-cause hospitalisation risk as the 348 
outcome provides different information and allows less targeted interventions. As with 349 
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Nirantharakumar et alǯ (5), this model has also not been externally validated in 350 
any independent population. 351 
Previous studies have not focussed on cardiovascular disease as both a major cause and 352 
cost for hospital admission among patients with diabetes. To understand the potential 353 
risk of cardiovascular hospitalisation in the next year, and the risk of a new episode 354 
(within 90 days) of a cardiovascular event (re-hospitalisation) could be helpful for 355 
clinicians to facilitate tailored, more intensive care to those with high risk profiles and to 356 
reduce hospitalisation inpatient cost. 357 
Conclusion and policy implication 358 
As far as we are aware, our study is the first study to develop prediction tools to estimate 359 
the 2-year risk of cardiovascular hospitalisation and re-hospitalisation within 90 days of a 360 
previous hospitalisation. Our two prediction models have two important implications for 361 
clinical practice. First, they can be used as tools to screen populations at high risk of 362 
cardiovascular hospitalisation and re-hospitalisation. Both algorithms are based on readily 363 
accessible clinical data routinely recorded in primary care and reviewed by diabetes 364 
management teams.  They can be readily integrated into primary care computer systems 365 
or developed into an app for a handheld device for ease of use. Secondly, our risk 366 
prediction models could be used to establish new treatment thresholds in clinical practice 367 
through consensus development of national guidelines. 368 
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FIGURE LEGENDS AND TABLES 467 
Figure-1. Assessing calibration in the derivation cohort (left) and the validation cohort 468 
(right) for cardiovascular hospitalisation (above panel) and cardiovascular re-469 
hospitalisation (below panel) 470 
 471 
Table-1. Baseline Characteristics of study populations. 472 
  
Derivation cohort 
 
External validation cohort 
 
N 4,704 1,121 
Cardiovascular hospitalisation, n (%) 588 (12.5) 183 (16.3) 
Cardiovascular rehospitalisation, n (%) 316 (6.7) 78 (7.0) 
Age, years 65.0±16.3 65.5±11.4 
Female, n (%) 1,919 (40.8) 444 (39.6) 
Systolic blood pressure, mmHg 134.5±16.0 139.7±20.2 
Diastolic blood pressure, mmHg 76.3±10.0 75.5±11.5 
Total cholesterol, mmol/L 4.3±1.2 4.2±1.7 
High density lipoprotein, mmol/L 1.3±0.6 1.1±1.2 
Low density lipoprotein, mmol/L 2.5±1.4 1.4±3.0 
Body mass index, kg/m2 30.8±6.9 32.2±6.0 
HbA1c, mmol/mol 61.5±17.2 56.2±15.1 
Lipid Lowering treatment, n (%) 3,342 (71.4) 731 (65.2) 
 473 
  474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
 482 
 483 
 484 
 485 
 486 
 487 
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 488 
 489 
Table-2. Final multivariate analysis for cardiovascular hospitalisation and re-hospitalisation 490 
risk among people with type 2 diabetes in derivation cohort 491 
Predictors Coefficient 95% Confidence Interval 
Cardiovascular Hospitalisation 
 ? ? ?  0.815914 (0.793045 to 0.838784) 
Male gender 0.228943 (0.206719 to 0.251168) 
 ? ? 57 mmol/mol (7.4%) -0.03967 (-0.06088 to -0.01846) 
(Body mass index/10)^-2 -1.85384 (-2.39533 to -1.31235) 
(Body mass index/10)^0.5 0.690585 (0.551284 to 0.829887) 
(Systolic blood pressure/100)^2 -0.40302 (-0.58492 to -0.22111) 
(Systolic blood 
pressure/100)^2*ln(Systolic blood 
pressure/100) 
0.966205 (0.758028 to 1.174381) 
(Diastolic blood pressure/100)^-2 0.474014 (0.387498 to 0.56053) 
(Diastolic blood pressure/100)^-
2*ln(Diastolic blood pressure/100) 
0.2724 (0.188226 to 0.356575) 
ln(Total cholesterol/10) 0.514695 (0.27381 to 0.75558) 
(Total cholesterol/10)^0.5 -1.05803 (-1.86382 to -0.25223) 
ln(High density lipoprotein) 0.073489 (0.04377 to 0.103208) 
(High density lipoprotein)^3 -0.02384 (-0.02699 to -0.02069) 
(Low density lipoprotein/10)^0.5 -0.55634 (-0.67239 to -0.44028) 
ln(Low density lipoprotein/10)* (Low 
density lipoprotein/10)^0.5 
-0.83161 (-1.01001 to -0.65322) 
Constant -3.80246 (-4.67529 to -2.92963) 
Cardiovascular Re-hospitalisation 
 ? ? ?  0.90054 (0.86384 to 0.93724) 
Male 0.22328 (0.188299 to 0.258261) 
 ? ? ? ?Ȁ (7.4%) 0.004076 (-0.0294 to 0.037547) 
(Body mass index/10)^-2 -4.17347 (-4.62492 to -3.72202) 
(Body mass index/10)^3 0.001821 (0.001318 to 0.002324) 
(Systolic blood pressure/100)^2 -1.16118 (-1.46728 to -0.85507) 
(Systolic blood pressure/100)^3 0.773551 (0.637616 to 0.909486) 
(Diastolic blood pressure/100)^-2 0.5875 (0.439237 to 0.735763) 
(Diastolic blood pressure/100)^-
2*ln(Diastolic blood pressure/100) 
0.4095  (0.260667 to 0.558332) 
 21 
 
(Total cholesterol/10)^-2 -0.00798 (-0.01031 to -0.00565) 
(Total cholesterol/10)^2 -0.02734 (-0.23117 to 0.176482) 
ln(High density lipoprotein/10) 0.051443 (0.004285 to 0.0986) 
(High density lipoprotein/10)^3 -0.02718 (-0.03277 to -0.02159) 
Low density lipoprotein/10 -1.34491 (-1.56307 to -1.12675) 
ln(Low density lipoprotein/10) -0.88347  (-1.28497 to -0.48196) 
Constant -4.55873 (-4.8866 to -4.23086) 
 492 
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Table-3. Model diagnostics (with 95% CI) 
 Derivation 
Validation Measure  Apparent performance Test performance 
Average 
optimism Optimism corrected 
 Cardiovascular Hospitalisation 
C statistic 0.7163 (0.7136 to 0.7190) 0.7027 (0.6996 to 0.7058) +0.0069 0.7094 (0.7067 to 0.7205) 0.7092 (0.7033 to 0.7151) 
Calibration slope 1.0000 (0.9806 to 1.0194) 0.9933 (0.9899 to 0.9966) +0.0067 0.9933 (0.9739 to 1.0127) 1.0001 (0.9807 to 1.0195) 
 Cardiovascular Re-hospitalisation 
C statistic 0.7154 (0.7113 to 0.7195) 0.7136 (0.7105 to 0.7167) +0.0036 0.7118 (0.7077 to 0.7159) 0.7098 (0.7014 to 0.7182) 
Calibration slope 1.0000 (0.9766 to 1.0234) 0.9976 (0.9949 to 1.0003) +0.0024 0.9976 (0.9742 to 0.9796) 0.9981 (0.9948 to 1.0482) 
 23 
 
Table-4. Predicted risk of cardiovascular hospitalisation and re-hospitalisation the validation cohort based on various cut-offs. 
  
Cut-off (%) for 
risk 
Mean 
predicted 
risk (%) Sensitivity (%) Specificity (%) 
Positive Predictive 
Value (%) 
Observed 
risk % 
Cardiovascular 
hospitalisation       
Top 5% 38.17 51.96 10.30 (9.70 to 10.90) 97.40 (97.20 to 97.50) 43.50 (41.50 to 45.50) 43.48 
Top 10% 31.73 43.35 17.50 (16.80 to 18.30) 94.60 (94.40 to 94.80) 38.60 (37.20 to 40.10) 38.62 
Top 15% 27.54 37.71 24.70 (23.90 to 25.60) 90.10 (89.80 to 90.40) 32.80 (31.80 to 33.90) 32.83 
Top 20% 24.53 33.77 34.00 (33.10 to 35.00) 84.60 (84.20 to 84.90) 30.10 (29.20 to 31.00) 30.09 
Top 25% 22.22 31.05 42.80 (41.80 to 43.80) 78.40 (78.00 to 78.70) 27.90 (27.20 to 28.60) 27.89 
Cardiovascular re-
hospitalisation        
Top 5% 11.34 15.86  26.20 (24.90 to 27.50)  91.20 (91.00 to 91.50)  18.30 (17.40 to 19.30)   18.33 
Top 10% 9.67 13.63 34.50 (33.10 to 36.00) 84.30 (84.00 to 84.60) 14.20 (13.50 to 14.90) 14.22 
Top 15% 8.69 12.59 40.50 (39.00 to 42.00) 79.10 (78.80 to 79.50) 12.70 (12.20 to 13.30) 12.73 
Top 20% 7.93 12.02 45.20 (43.70 to 46.70) 75.90 (75.50 to 76.30) 12.40 (11.90 to 12.90) 12.37 
Top 25% 7.16 11.46 50.00 (48.50 to 51.50) 72.40 (72.00 to 72.70) 12.00 (11.50 to 12.50) 11.98 
 

Supplemental Table-1. Univariate analysis for cardiovascular hospitalisation and re-hospitalisation 
risk among people with type 2 diabetes in derivation cohort 
 
Predictors Coefficient 95% Confidence Interval 
Cardiovascular Hospitalisation 
 ? ? ?  0.846665 (0.8262905 to 0.8670392) 
Male gender 0.176845 (0.1563107 to 0.1973798) 
 ? ? ? ?Ȁ -0.133750 (-0.1537015 to -0.1137988) 
(Body mass index/10)^-2 -3.814109 (-4.339377 to -3.288841) 
(Body mass index/10)^0.5 -0.175857 (-0.3110282 to -0.0406859) 
(Systolic blood pressure/100)^2 -0.326099 (-0.4951727 to -0.157025) 
(Systolic blood pressure/100)^2*ln(Systolic blood pressure/100) 0.899080 (0.7036069 to 1.094553) 
(Diastolic blood pressure/100)^-2 0.288490 (0.255288 to 0.3216911) 
(Diastolic blood pressure/100)^-2*ln(Diastolic blood pressure/100) 0.123622 (0.0999253 to 0.1473193) 
ln(Total cholesterol/10) 2.518678 (2.307047 to 2.73031) 
(Total cholesterol/10)^0.5 -8.727267 (-9.433486 to -8.021047) 
ln(High density lipoprotein) 0.088652 (0.061444 to 0.1158604) 
(High density lipoprotein)^3 -0.037348 (-0.0403706 to -0.0343245) 
(Low density lipoprotein/10)^0.5 -0.741638 (-0.849156 to -0.6341195) 
Ln(Low density lipoprotein/10)* (Low density lipoprotein/10)^0.5 -1.234349 (-1.402307 to -1.066391) 
Cardiovascular Re-hospitalisation 
 ? ? ?  0.929657 (0.8966139 to 0.962701) 
Male gender 0.179317 (0.1465089 to 0.2121253) 
 ? ? ? ?Ȁ -0.097652 (-0.1294095 to -0.0658946) 
(Body mass index/10)^-2 -3.526998 (-3.948076 to -3.105919) 
(Body mass index/10)^3 0.000793 (0.0002554 to 0.0013296) 
(Systolic blood pressure/100)^2 -0.854411 (-1.140125 to -0.5686968) 
(Systolic blood pressure/100)^3 0.645979 (0.5180567 to 0.7739015 
(Diastolic blood pressure/100)^-2 0.224379 (0.1539288 to 0.2948295) 
(Diastolic blood pressure/100)^-2*ln(Diastolic blood pressure/100) 0.101419 (0.0399049 to 0.1629332) 
(Total cholesterol/10)^-2 -0.000040 (-0.0002732 to 0.0001938) 
(Total cholesterol/10)^2 -0.728174 (-0.8790058 to -0.5773416) 
ln(High density lipoprotein/10) 0.089334 (0.0450915 to 0.1335771) 
(High density lipoprotein/10)^3 -0.046205 (-0.0516534 to -0.0407557) 
Low density lipoprotein/10 -2.005945 (-2.203394 to -1.808495) 
Low density lipoprotein/10*Ln(Low density lipoprotein/10) -1.326986 (-1.711652 to -0.9423188) 
 
 
 
 
Supplemental Chart-1. Practical prognostic score charts for predicting cardiovascular hospitalisation and re-hospitalisation 
Clinical example: type 2 diabetes patient aged 75 years, female gender, 69.6mmol/mol (8.5%) HbA1c, 29.6kg/m2 of body mass index, 102 mmHg systolic blood pressure, 
60mmHg diastolic blood pressure, 6.7mmol/L  triglyceride, 1.5mmol/L high density lipoprotein, 1.8mmol/L low density lipoprotein. 
A: Prognostic score chart for predicting cardiovascular hospitalisation 
Left chart of prognostic score Right chart of prognostic score 
Predictors Description Value Score Score range Figure-2. Graphical illustration of cardiovascular hospitalisation 
prognostic score for the clinical example. Age  ? ? ? =1 1 82 [0 to 82] 
Gender Male gender=1 0 0 [0 to 11] 
 
HbA1c  ? ? ? ?Ȁȋ ?Ǥ ? ?Ȍ=1 1 -2 [-2 to 0] 
Body mass index-1 (Body mass index/10)^-2 0.11 -11 [-27 to -3] 
Body mass index-2 (Body mass index/10)^0.5 1.72 59 [13 to 78] 
Systolic blood 
pressure-1 
(Systolic blood pressure/100)^2 
1.04 -21 [-65 to -20] 
Systolic blood 
pressure-2 
(Systolic blood 
pressure/100)^2*ln(Systolic blood 
pressure/100) 
0.02 1 [0 to 92] 
Diastolic blood 
pressure-1 
(Diastolic blood pressure/100)^-2 
2.78 66 [12 to 87] 
Diastolic blood 
pressure-2 
(Diastolic blood pressure/100)^-
2*ln(Diastolic blood pressure/100) 
-1.42 -19 [-33 to -1] 
Total cholesterol-1 ln(Total cholesterol/10) -0.40 -10 [-56 to -7] 
Total cholesterol-2 (Total cholesterol/10)^0.5 0.82 -43 [-46 to -18] 
High density 
lipoprotein-1 
ln(High density lipoprotein) 
0.41 1 [-5 to 5] 
High density 
lipoprotein-2 
(High density lipoprotein)^3 
3.38 -4 [-35 to 0] 
Low density 
lipoprotein-1 
(Low density lipoprotein/10)^0.5 
0.42 -12 [-22 to -5] 
Low density 
lipoprotein-2 
ln(Low density lipoprotein/10)* (Low 
density lipoprotein/10)^0.5 
-0.73 30 [15 to 31] 
Constant Constant=1 1 -190 [-190 to -190] 
Sum Score -73  
Predicted probability of cardiovascular hospitalisation 18.9% 
B: Prognostic score chart for predicting cardiovascular re-hospitalisation 
Left chart of prognostic score Right chart of prognostic score 
  Value Score Score range Figure-3. Graphical illustration of cardiovascular re-
hospitalisation prognostic score for the clinical example. Age  ? ? ? ? ? 1 90 [0 to 90] 
Gender Male 0 0 [0 to 11] 
 
HbA1c  ? ? ? ?Ȁȋ ?Ǥ ? ?Ȍ ? ? 1 0.2 [-2 to 0] 
Body mass index-1 (Body mass index/10)^-2 0.11 -24 [-61 to -8] 
Body mass index-2 (Body mass index/10)^3 25.93 2 [1 to 13] 
Systolic blood 
pressure-1 
(Systolic blood pressure/100)^2 1.04 -60 [-187 to -58] 
Systolic blood 
pressure-2 
(Systolic blood pressure/100)^3 1.06 41 [38 to 225] 
Diastolic blood 
pressure-1 
(Diastolic blood pressure/100)^-2 2.78 82 [29 to 109] 
Diastolic blood 
pressure-2 
(Diastolic blood pressure/100)^-
2*ln(Diastolic blood pressure/100) 
-1.42 -29 [-49 to -2] 
Total cholesterol-1 (Total cholesterol/10)^-2 2.23 -1 [-33 to -1] 
Total cholesterol-2 (Total cholesterol/10)^2 0.45 -1 [-1 to 0] 
High density 
lipoprotein-1 
ln(High density lipoprotein/10) 0.41 1 [-4 to 3] 
High density 
lipoprotein-2 
(High density lipoprotein/10)^3 3.38 -5 [-40 to ] 
Low density 
lipoprotein-1 
Low density lipoprotein/10 0.18 -12 [-43 to -2] 
Low density 
lipoprotein-2 
ln(Low density lipoprotein/10) -0.31 14 [4 to 16] 
Constant Constant=1 1 -228 [-228 to -228] 
Sum Score -129  
Predicted probability of cardiovascular hospitalisation 7.0% 
 
 
 
